Masimo SET^®: Clinically Proven

The accuracy and reliability of Masimo SET^® pulse oximetry have been studied in challenging conditions

Home / Masimo SET^®: Clinically Proven

Over 100 independent and objective studies have shown that Masimo SET^® outperforms other pulse oximetry technologies.¹

On a post-surgical unit it was found that:
- Rescue calls and ICU transfers were reduced by 65% and 48%, respectively, after the implementation of continuous surveillance monitoring with Masimo SET^®.²
- Over five years, clinicians achieved their goal of zero preventable deaths or brain damage due to opioids.³
- Over ten years, clinicians maintained a 50% reduction in unplanned transfers and a 60% reduction in rescue events, despite increases in patient acuity and occupancy.⁴
In a PACU, Masimo SET^® had a greater than 50% reduction in false alarms compared to other pulse oximetry technology.⁵

In a study of 122,738 infants, critical congenital heart disease (CCHD) screening sensitivity increased from 77% to 93% with the combined use of Masimo SET^® and clinical assessment.⁶
In a study of 39,821 infants, CCHD screening sensitivity increased from 63% with physical exam alone to 83% with physical exam and Masimo SET^® pulse oximetry.⁷
In two NICU settings, Masimo SET^®, coupled with changes in clinical practice, showed significantly reduced rates of severe retinopathy of prematurity (ROP) and decreased the need for laser treatment.^8,9
Researchers showed time to reliable oxygen saturation readings during neonatal resuscitation was approximately 50 seconds faster using Masimo SET^® than using other pulse oximetry technologies.¹⁰

“I saw and was conquered. I was not able to defeat the Masimo SET^® pulse oximeter using all the motion and low pulse tricks I know. This technology is most impressive and should be available in all oximeters.”

John Severinghaus, M.D.
Professor of Anesthesiology, Emeritus University of California, San Francisco

The Performance of Masimo SET^®

CCHD Screening

Improved Critical Congenital Heart Disease Screening
Sensitivity vs. Clinical Assessment Alone

When combined with clinical assessment, Masimo SET^® improved critical congenital heart disease (CCHD) screening sensitivity to 93%⁶

Retinopathy of Prematurity

Severe Retinopathy of Prematurity Rate

Masimo SET^®, coupled with changes in clinical practice, led to a significant reduction in rates of severe retinopathy of prematurity (ROP)⁸

Performance During Motion and Low Perfusion

Masimo - Performance through Low Performance Chart

Masimo SET^® had 3% missed true alarms and 5% false alarms versus 43% and 28%, respectively, using competitor technology^11*

*Results shown are calculated by combining sensitivity and specificity outcomes of machine-generated and volunteer-generated motion.

Learn More About Masimo SET^®

SET^® Pulse Oximetry

CCHD Screening

References:

^1.
Published clinical studies on pulse oximetry and the benefits of Masimo SET^® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
^2.
Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
^3.
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
^4.
McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
^5.
Malviya S et al. False Alarms and Sensitivity of Conventional Pulse Oximetry Versus the Masimo SET^® Technology in the Pediatric Postanesthesia Care Unit. Anesth Analg 2000; 90(6):1336-1340.
^6.
Zhao et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet 2014 Aug 30;384(9945):747-54.
^7.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ 2009;338:a3037.
^8.
Castillo et al. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO₂ Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
^9.
Sola et al. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 2003;111(2):339-345.
^10.
Baquero H et al. Avoiding Hyperoxemia during Neonatal Resuscitation: Time to Response of Different SpO₂ Monitors. Acta Paediatr. 2011 Apr;100(4):515-8.
^11.
Shah et al. Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers. J Clin Anesth. 2012;24(5):385-91.